Document is current
Any future updates will be listed below
-
Authors
Duque, Sofia https://orcid.org/0000-0001-9273-5650
Marinho, António https://orcid.org/0000-0002-3295-6723
Almeida, Paulo https://orcid.org/0000-0002-4879-559X
Marques Pereira, Raul https://orcid.org/0000-0001-8678-4325
Buzaco, Rui https://orcid.org/0000-0003-0181-3081
-
Funding
Funding for this research was provided by:
GlaxoSmithKline (This study was funded by GlaxoSmithKline, which had no role in the decision of the content of the article.)
Universidade de Lisboa
- License Information
-
More Information
Article History
Accepted: 21 November 2024
First Online: 15 January 2025
Declarations
:
: Open access funding provided by FCT|FCCN (b-on). This study was funded by GlaxoSmithKline, which had no role in decisions about the content of the article.
: SD, AM, PA, and RB have received lecture fees from GlaxoSmithKline. RMP has no competing interests to declare that are relevant to the content of this article.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: This article was developed based on input from the expert advisors (SD, AM, PA, RMP, and RB), who attended three virtual roundtable meetings in February and March 2023. All authors made substantial contributions to the preparation of this article, critical evaluation, and revision of all drafts. All authors read and approved the final manuscript.
